The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Tuesday, 14 May 2025 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed…
“A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to…
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant new tender in Udine, Italy, valued at SEK 61.8 million over a 36-month period.…
On Tuesday April 29 at 11:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q1 2025 report (which will have been published earlier on April 29 at 10:00 a.m.…
Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science…
Devyser´s annual report 2024 has today been published on the company´s website.The report is available on: https://investors.devyser.com/en/reports-presentationsThe financial year covers…
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Devyser Genomic Laboratories, Roswell, Georgia, based on the results of a recent…
Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical…
Devyser issues a correction to the year-end report for 2024 that was sent out earlier today, where an incorrect distribution of the quarter's net sales between direct sales and…
“Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of…
